Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tvardi Operating Company, Inc. maintains a patent portfolio currently focused within the Biotechnology & Pharmaceuticals technology area. The portfolio shows 1 pending office action, which represents the total active workload for the company. This activity is confined to 1 distinct art unit, suggesting that the current legal efforts are concentrated in a specific technical niche rather than spread across various regulatory silos.
The prosecution is handled by a distinct examiner, identifying BORI, IBRAHIM D as the primary point of contact. This individual is the busiest examiner for the portfolio with a busiest examiner pending action. Because the pending office action is assigned to this examiner, the practitioner faces a streamlined interaction model. There is no variance in examiner behavior to account for across the portfolio. The distinct examiner and art unit count indicate a focus in the current prosecution cycle. This concentration allows for a specialized approach to the pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 1 | 43.8% | +38.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18447040 | THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOF | BORI, IBRAHIM D | 52d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18447040 | THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOF | BORI, IBRAHIM D | 1629 | §103§112DP | Final Rejection | 52d overdue | Pending | Aug 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial